Drug Trial Radar · NCT05106179
The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma
Last checked: Nov 20, 2026Latest source record: Nov 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Dec 2021
Primary completion
Dec 2022
Study completion Dec 2023
Sponsor
- Lead sponsor
- Center for Vascular Pathology, MoscowAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Spinal hemangioma is one of the most common benign vertebral tumours. Being mostly asymptomatic, it is still associated with a pain syndrome especially if encroaches into the neural canal. This study is organised to evaluate the efficacy and safety of β-blockers drugs in adults with spinal hemangioma.
Conditions
- Spinal Tumor
- Spinal Hemangioma
- Beta Blocker Toxicity
Interventions
Atenolol PillDrug
Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.
Propranolol PillDrug
Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reducing tumor growthTime frame: 3 months
- Reducing tumorTime frame: 6 months
- Life-qualityTime frame: 3 months and 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Vascular Anomalies Center (VAC) "Hemangioma"
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.